Abstract
Effect of High-dose Telmisartan on the Prevention of Recurrent Atrial Fibrillation in Hypertensive Patients
Highlights
It is well known that angiotensin-converting enzyme (ACE) inhibitors and angiotensin-II typeI receptor blockers (ARBs) are effective in treating hypertension and in reducing the morbidity and mortality in various disease conditions including atrial fibrillation (AF),[1] coronaryCorresponding Address : Shingo Maeda, MD, 1-26-1 Kyonancho, Musashino-city, Tokyo, 180-8610, Japan.Journal of Atrial FibrillationOriginal Research artery disease (CAD),[2] and congestive heart failure (CHF).[3]
The patients were eligible for this study if they were older than 30 years old and had essential hypertension with a systolic blood pressure (SBP) of > 140 mmHg and/or diastolic blood pressure (DBP) of > 90 mmHg
We presented the results from the univariate and multivariate models that were controlled for the incidence of AF, age, sex, history of CHF, taking ACE inhibitors or beta-blockers, left atrial dimension (LAD), left ventricular ejection fraction (LVEF) and BNP level
Summary
It is well known that angiotensin-converting enzyme (ACE) inhibitors and angiotensin-II type. I receptor blockers (ARBs) are effective in treating hypertension and in reducing the morbidity and mortality in various disease conditions including atrial fibrillation (AF),[1] coronary. Original Research artery disease (CAD),[2] and congestive heart failure (CHF).[3] The action of high-dose telmisartan was shown to be equivalent to that of highdose ramipril in preventing cardiovascular events in the Ongoing Telmisartan Alone in Combination with Ramipril Global Endpoint Trial (ONTARGET).[4] It is not known, whether lowdose telmisartan can exert as effective an action as high-dose telminsartan in preventing cardiovascular events. Telmisartan has been shown to exert an equivalent action as ramipril on the prevention of cardiovascular events, but the dose-dependent actions of telmisartan on the prevention of events remain unknown
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
